Tag archive for ‘EpiPen’
Comments on Agenus and Antares
SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]
Comments on Antares, Kite Pharma and Northwest Biotherapeutics
SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]
Antares: Detailed Sales and Earnings Projections for 2015 and 2016 (ATRS, Buy, $2.77, subscription required)
Investment Thesis I continue with my long standing recommendation on Antares. Last year was a disappointing year for the stock, but the basic reasons for my positive view of the Company remain largely intact. I discussed this is detail in my report of November 23, 2004 called Antares: 2015 Could Be the Breakout Year for […]
Antares: Responding to Two Questions on Teva’s AB Rated Competitor to EpiPen (ATRS, Buy, $2.44)
Purpose of the Blog I very much appreciate questions and feedback from subscribers to my website. I have had two recent questions that I have responded to that may be of interest to other investors interested in the Teva collaboration with Antares to develop an AB rated generic equivalent to Mylan’s EpiPen. For more details […]